前列腺癌PSMA放射配体诊疗:原理、实践与未来展望
本文聚焦前列腺特异性膜抗原(PSMA)放射配体诊疗,重点讨论镥-177(177Lu)-PSMA放射配体治疗作为转移性去势抵抗性前列腺癌的新兴治疗方式。美国FDA批准177Lu-PSMA-617基于VISION试验显示的总生存期和生活质量改善,PSMA PET评估的PSMA表达对患者筛选和治疗资格评估至关重要。文章还讨论了给药、剂量和副作用等当前实践,以及PSMA PET疗效评估标准(仍需进一步验证)和未来方向。
要点
- PSMA PET评估的PSMA表达是患者筛选和治疗资格评估的关键。
- 177Lu-PSMA-617获FDA批准基于VISION试验显示的总生存期和生活质量改善。
- PSMA PET疗效评估标准仍需进一步验证。
核心结论
- PSMA放射配体治疗在前列腺癌治疗格局中具有重要作用,并有望改善患者结局。
研究设计与样本
- 综述,聚焦PSMA放射配体诊疗,特别是177Lu-PSMA放射配体治疗;基于VISION试验等证据。
诊断标准与关键数值
- PSMA表达通过PSMA PET评估,用于患者筛选和治疗资格评估。
- PSMA PET疗效评估标准仍需进一步验证。
临床应用与阅片要点
- 作者讨论了当前实践,包括治疗给药、剂量和副作用,重点关注资格标准和治疗后影像的附加价值。
局限性
- PSMA PET疗效评估标准仍需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Prostate cancer is a leading cause of cancer-related mortality in men, with metastatic castration-resistant prostate cancer presenting a substantial treatment challenge. The authors focuse on prostate-specific membrane antigen (PSMA) radiotheranostics, particularly lutetium 177 (177Lu)-PSMA radioligand therapy, as an emerging treatment modality for metastatic castration-resistant prostate cancer. The U.S. Food and Drug Administration approval of 177Lu-PSMA-617 marked a substantial advancement in the treatment paradigm of metastatic castration-resistant prostate cancer, based on the VISION trial that showed improved overall survival and quality of life compared with those for standard care. PSMA expression, assessed via PSMA PET, is crucial for patient selection and assessment of treatment eligibility. The authors discuss current practices, including therapy administration, dosing, and side effects, with a particular focus on eligibility criteria and the added value of posttherapy imaging. Response assessment criteria using PSMA PET are discussed, although these require further validation. The discussion of future directions highlights ongoing trials investigating PSMA targeting agents, the extension of radioligand therapy to earlier stages of prostate cancer, and combination therapies. This review underscores the role of PSMA radioligand therapy in the evolving landscape of prostate cancer treatment and its promise for improving patient outcomes. ©RSNA, 2024 Supplemental material is available for this article.
引用
- Szidonya LK, Barwick TD, Challapalli A, et al. PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects. Radiographics. 2024. PMID: 39570783. doi:10.1148/rg.240080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。